Atricure (ATRC) AI Stock Analysis

• Market Cap: $1.65B
• Dividend Yield: N/A
• Average Volume (3M): 548.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 15.80%
• EPS Growth: 26.94%
• Country: US
• Employees: 1,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 49,716,988
• 10 Day Avg. Volume: 514,129
• 30 Day Avg. Volume: 548,702
• PEG Ratio: -0.73
• Price to Book (P/B): 3.11
• Price to Sales (P/S): 3.08
• P/FCF Ratio: -127.52
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 3.13
• Enterprise Value/Gross Profit: 4.19
• Enterprise Value/Ebitda: -259.54
• 1Y Price Target: $52.60
• Price Target Upside: 59.88% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.49
• Revenue Forecast (FY): $530.70M

• Rating: 65 Neutral
• Price Target: $37.00 ▲(12.46% Upside)

Atricure's strong earnings call performance and improved cash flow management are significant positives, indicating robust growth and innovation. However, the company's current unprofitability and bearish technical indicators present challenges. Addressing profitability and improving market sentiment will be crucial for enhancing the stock's attractiveness.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.

Product Innovation

Innovative product launches enhance competitive positioning and drive revenue growth, sustaining market leadership.

Cash Flow Improvement

Improved cash flow and EBITDA reflect operational efficiency, providing financial flexibility for future investments.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder financial health, requiring strategic focus to enhance shareholder value.

Minimally Invasive Ablation Decline

Declining sales in key segments could impact growth, necessitating strategic adjustments to regain market share.

Hybrid Therapy Market Challenges

Competitive pressures from new technologies may limit market penetration, requiring innovation to maintain relevance.

Atricure Business Overview & Revenue Model

Company Description

AtriCure, Inc. is a medical device company specializing in innovative solutions for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. Founded in 2000 and headquartered in Mason, Ohio, AtriCure develops and manufactures a range of products specifically designed to improve patient outcomes in heart surgery. Its core offerings include energy-based devices for cardiac ablation procedures, as well as accessories and surgical tools that enhance the effectiveness of these interventions. AtriCure operates primarily within the cardiology and surgical sectors, focusing on advancing minimally invasive techniques.

How the Company Makes Money

AtriCure generates revenue primarily through the sale of its medical devices and related products. Key revenue streams include the direct sale of its ablation devices, which are used in surgical procedures to treat atrial fibrillation, as well as the sale of accessories and consumables necessary for these procedures. The company also benefits from recurring revenue through the ongoing use of its devices in hospitals and surgical centers. Additionally, AtriCure has established partnerships with various healthcare institutions and providers, which help to expand its market reach and enhance its service offerings. Factors contributing to its earnings include the increasing prevalence of atrial fibrillation, the growing acceptance of minimally invasive surgical techniques, and ongoing innovation in its product line.

Atricure Financial Statement Overview

Summary

Atricure demonstrates solid revenue growth and efficient production, but faces profitability challenges. The balance sheet is stable with low leverage, yet shareholder returns are negative. Cash flow improvements are promising, reflecting better cash management. Addressing profitability issues will be key to enhancing overall financial health.

Income Statement

Atricure's income statement shows a positive revenue growth rate of 3.67% TTM, indicating a steady increase in sales. However, the company is facing challenges with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong at approximately 74.87%, suggesting efficient production processes. Overall, while revenue is growing, the company needs to address its profitability issues to improve its financial health.

Balance Sheet

The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.15, indicating conservative leverage. However, the return on equity is negative, highlighting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a strong capital structure. Overall, the balance sheet is stable, but improving profitability would enhance shareholder value.

Cash Flow

Atricure's cash flow statement shows a significant improvement in free cash flow growth at 153.43% TTM, indicating better cash management. The operating cash flow to net income ratio is below 1, suggesting that operating activities are not fully covering net losses. Despite this, the positive trend in free cash flow is a strong indicator of improving operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	518.30M	465.31M	399.25M	330.38M	274.33M	206.53M
Gross Profit	388.06M	347.52M	300.37M	245.94M	205.86M	149.31M
EBITDA	-6.26M	-18.53M	-8.11M	-29.50M	65.75M	-33.61M
Net Income	-28.77M	-44.70M	-30.44M	-46.47M	50.20M	-48.16M
Balance Sheet
Total Assets	635.44M	609.33M	613.93M	585.45M	615.31M	714.54M
Cash, Cash Equivalents and Short-Term Investments	147.87M	122.72M	137.28M	121.11M	119.09M	244.22M
Total Debt	73.73M	76.53M	74.49M	74.55M	75.65M	74.00M
Total Liabilities	158.94M	148.36M	147.76M	128.69M	131.56M	302.14M
Stockholders Equity	476.51M	460.97M	466.17M	456.75M	483.76M	412.39M
Cash Flow
Free Cash Flow	16.00M	-11.26M	-37.51M	-39.02M	-23.53M	-25.13M
Operating Cash Flow	43.14M	12.20M	4.48M	-22.14M	-13.78M	-19.87M
Investing Cash Flow	-26.64M	30.23M	21.82M	44.01M	23.50M	-156.20M
Financing Cash Flow	816.00K	-3.60M	-32.00K	-7.06M	-7.64M	189.39M

Atricure Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 32.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRC, the sentiment is Neutral. The current price of 32.9 is below the 20-day moving average (MA) of 33.88, below the 50-day MA of 35.07, and below the 200-day MA of 34.38, indicating a neutral trend. The MACD of -0.69 indicates Negative momentum. The RSI at 50.97 is Neutral, neither overbought nor oversold. The STOCH value of 72.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATRC.

Atricure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	75 Outperform	$1.95B	41.90	15.02%	0.88%	13.07%	27.98%
ATRC	65 Neutral	$1.65B	―	-6.11%	―	15.80%	26.94%
TFX	60 Neutral	$4.83B	―	-7.90%	1.29%	5.43%	-245.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QDEL	45 Neutral	$1.43B	―	-44.21%	―	-3.43%	38.98%
PLSE	44 Neutral	$881.66M	-11.46	-86.99%	―	―	-40.63%
NVCR	39 Underperform	$1.26B	―	-50.60%	―	11.17%	-15.64%

Atricure Corporate Events

AtriCure’s Earnings Call Highlights Robust Growth and Innovation

AtriCure, Inc. recently held an earnings call that showcased a robust performance, marked by significant revenue growth, improved profitability, and successful product launches. Despite facing some challenges in specific markets, the company remains well-positioned with a strong cash position and has raised its guidance for the year, reflecting a positive outlook.

AtriCure, Inc. Reports Strong Q3 2025 Results

AtriCure, Inc., a prominent player in the medical device sector, specializes in innovative surgical treatments for atrial fibrillation and related conditions, with a focus on post-operative pain management. In its latest earnings report, AtriCure announced a significant 15.8% increase in worldwide revenue for the third quarter of 2025, reaching $134.3 million. The company also reported a net loss of $0.3 million, showing a substantial improvement of $7.6 million compared to the previous year, alongside an adjusted EBITDA increase of $9.9 million. Key drivers of this growth include the successful adoption of products like the AtriClip platform and cryoSPHERE devices, as well as the EnCompass clamp. The U.S. market saw a 14.5% revenue increase, while international revenue surged by 22.0%, reflecting strong global demand. Looking ahead, AtriCure has raised its financial outlook for 2025, projecting full-year revenue between $532 million and $534 million, with adjusted EBITDA expected to range from $55 million to $57 million. The company remains focused on product innovation and expanding its market presence, aiming for continued growth and profitability.

AtriCure’s Ongoing Study: Implications for Cardiac Treatment and Market Performance

Study Overview: AtriCure, Inc. is conducting a multicenter patient registry titled ‘A Multicenter Patient Registry for Outcomes of Inappropriate Sinus Tachycardia and Postural Orthostatic Tachycardia Syndrome Treatment.’ The study aims to gather real-world safety and performance data on AtriCure devices used for ablating cardiac tissue in treating Inappropriate Sinus Tachycardia (IST) and Postural Tachycardia Syndrome (POTS). This research is significant as it seeks to enhance treatment outcomes for these conditions.

AtriCure’s Cryoablation Study: A New Frontier in Pain Management

Study Overview: The clinical study titled ‘Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain (VANISH)’ aims to evaluate the usage of AtriCure’s cryoablation device in nerve freezing during amputation procedures. The study seeks to gather real-world data on the safety and performance of this device, which is significant for improving post-operative and phantom limb pain management.

AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study

Study Overview: The TRAC-AF Registry, officially titled ‘A Multicenter Patient Registry for Outcomes From Comprehensive Ablation Treatments of Atrial Arrhythmias,’ aims to gather real-world data on the safety and effectiveness of AtriCure devices used in open heart and hybrid ablation procedures. This study is significant as it seeks to improve treatment outcomes for patients with atrial fibrillation, a common heart condition.

AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation

Study Overview: The BoxX-NoAF Clinical Trial, officially titled EnCompass Clamp and the AtriClip in Box Lesion and Left Atrial Appendage EXclusion Procedure for the Prevention of New Onset of Atrial Fibrillation, aims to address the high incidence of Post Operative Atrial Fibrillation (POAF) in cardiac surgery patients. This randomized trial evaluates whether prophylactic ablation and exclusion of the Left Atrial Appendage during routine cardiac surgery can reduce the incidence of POAF and long-term clinical atrial fibrillation in at-risk patients.

AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia

Study Overview: The HEAL-IST IDE Trial, officially titled ‘Hybrid Epicardial and Endocardial Sinus Node Sparing Ablation Therapy for Inappropriate Sinus Tachycardia,’ aims to assess the safety and effectiveness of a novel ablation procedure for treating Inappropriate Sinus Tachycardia (IST). This condition significantly impacts the quality of life of younger patients, and the trial seeks to provide systematic clinical evidence for a new treatment option.

AtriCure’s Cryoanalgesia Study: A Potential Game-Changer in Post-Operative Pain Management

Study Overview: The clinical study titled The CryoICE™ Cryoanalgesia Registry for Pain Management in Post-cardiothoracic Surgery Via Cryoablation of the Intercostal Nerves aims to evaluate the outcomes of cryoablation of intercostal nerves for managing post-operative pain. This multicenter patient registry is significant as it seeks to improve pain management strategies following cardiothoracic surgery.

AtriCure Reports Strong Q2 Earnings with Record Growth

AtriCure, Inc. recently held its earnings call, reflecting a strong quarter marked by significant revenue growth across multiple segments and the successful completion of a major clinical trial enrollment. Despite facing challenges in the hybrid therapy segment due to competitive pressures and a slight decrease in gross margin, the overall performance and strategic direction of the company remain positive.